OTC: AAVXF - ABIVAX Société Anonyme

Lønnsomhet i seks måneder: -51.35%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan ABIVAX Société Anonyme

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet ABIVAX Société Anonyme

ABIVAX Société Anonyme, a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. The company is also developing obefazimod in Phase IIb/III pivotal planned studies for the treatment of Crohn's Disease; and completed Phase IIa clinical trials for the treatment of rheumatoid arthritis diseases.

flere detaljer
In addition, the company develops ABX 196, an immune enhancer candidate that is in Phase 1/2 POC clinical trial for the treatment of hepatocellular cancer, as well as a pre-clinical drug for the treatment of respiratory syncytial virus. It has license agreement with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета eur
Сайт https://www.abivax.com
Цена ао 11.05
Prisendring per dag: 0% (7.37)
Prisendring per uke: -33.3% (11.05)
Prisendring per måned: -33.3% (11.05)
Prisendring over 3 måneder: -33.3% (11.05)
Prisendring over seks måneder: -51.35% (15.15)
Prisendring per år: -27.67% (10.19)
Prisendring over 3 år: -76.97% (32)
Prisendring over 5 år: -26.15% (9.98)
Prisendring over 10 år: 0% (7.37)
Prisendring siden begynnelsen av året: -33.3% (11.05)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 86.25 1
P/BV 2.03 7
P/E 0 0
EV/EBITDA -1.54 0
Total: 4

Effektivitet

Navn Betydning Karakter
ROA, % -45.17 0
ROE, % -75.37 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.4212 10
Total: 9.6

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 19991.3 10
Lønnsomhet Ebitda, % 300.08 10
Lønnsomhet EPS, % 15.22 3
Total: 8.6
Flere detaljer

Institusjoner Volum Dele, %
iShares MSCI EAFE Small Cap ETF 72366 0.12
abrdn World Healthcare Fund 37000 0.06
College Retirement Equities Fund-Stock Account 26827 0.04
Fidelity SAI International Small Cap Index Fund 9418 0.01
SSgA SPDR ETFS Europe I-SPDR MSCI Europe Small Cap UCITS ETF 7659 0.01
State Street Inst Inv Tr-State St All Cap Glb Equity ex-US Index Port 3874 0.01
iShares MSCI Europe Small Cap ETF 3094 0
SSgA SPDR ETFS Europe I-SPDR MSCI Europe Small Cap Value Weighted 2172 0
SPDR (R) Portfolio Europe ETF 520 0
DBX ETF Trust-X-trackers MSCI Eurozone Hedged Equity 194 0



Veileder Stillingstittel Betaling Fødselsår
Dr. Philippe Pouletty M.D., Ph.D. Founder & Director N/A 1958 (67 år)
Mr. Marc M. P. de Garidel M.B.A. CEO & Director 850.26k 1958 (67 år)
Mr. Didier Blondel EVP, CFO & Board Secretary N/A 1964 (61 år)
Mr. Didier Scherrer Ph.D. Chief Scientific Officer N/A 1970 (55 år)
Mr. Patrick Malloy Senior Vice President of Investor Relations N/A
Ms. Ida Hatoum Chief People & Compliance Officer N/A 1975 (50 år)
Mr. Pierre Courteille M.B.A. Chief Business Officer N/A 1969 (56 år)
Mr. Michael Ferguson B.S., M.B.A. Chief Commercial Officer N/A 1978 (47 år)
Mr. Jerome Denis Ph.D. Executive Vice President of Process Development & Manufacturing N/A
Ms. Ana Sharma M.P.H. VP & Global Head of Quality

Adresse: France, Paris, 7-11 boulevard Haussmann - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.abivax.com